Tumor Treating Fields and Combination Therapy in Management of Brain Oncology
Open Access
Abstract
Glioblastoma (GBM) remains a challenging cancer to treat with limited effective therapies. Standard treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, offer marginal survival benefits but are often limited by side effects and drug resistance. Temozolomide is the most commonly used chemotherapy; however, resistance and lack of efficacy in recurrent GBM hinder its success. Tumor treating fields (TTFields), a novel non-invasive modality that utilizes alternating electric fields, have recently emerged as a promising treatment for GBM. TTFields work by disrupting the function of the mitotic spindle and inducing apoptosis in cancer cells. They can be especially effective when combined with other therapies. TTFields enhance drug delivery when paired with chemotherapy by increasing the permeability of the blood–brain barrier and cell membranes, leading to more effective tumor inhibition. Similarly, TTFields increase cancer cell sensitivity to radiation therapy and improve the efficacy of targeted therapies, such as sorafenib and immunotherapy, particularly in extra-cranial tumors. The Optune device, the primary medical device for TTFields’ delivery, offers a convenient and versatile treatment option, allowing remote care and exhibiting fewer adverse effects. This review discusses the potential of TTFields as a valuable addition to GBM treatment, particularly in combination therapies, and highlights the device’s clinical applications.Keywords
Funding Information
- Baylor Scott and White Match Fund (RP240537)
This publication has 94 references indexed in Scilit:
- Targeted sonodynamic therapy induces tumor cell quasi-immunogenic ferroptosis and macrophage immunostimulatory autophagy in glioblastomaBiomaterials, 2024
- Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft modelCancer Immunology, Immunotherapy, 2024
- Potassium channel-driven bioelectric signalling regulates metastasis in triple-negative breast cancerEBioMedicine, 2021
- Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updatesCritical Reviews in Oncology/Hematology, 2021
- Toward Hijacking Bioelectricity in Cancer to Develop New Bioelectronic MedicineAdvanced Therapeutics, 2021
- Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyCancer Immunology, Immunotherapy, 2020
- Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating Fields (TTFields) in Vitro and In VivoInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategyJournal of Cancer Research and Clinical Oncology, 2019
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017